PDGF: A Literature Course on What the Published Research Reports

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question. It summarises what a set of published papers on platelet-derived growth factor (PDGF) reported, in their own terms, and it does not tell anyone to use anything.

Course map

1. Module 1 — what PDGF is and how it has been studied
2. Module 2 — mechanism as described in the literature
3. Module 3 — reported outcomes, study by study
4. Module 4 — PDGF side effects: what studies report
5. Module 5 — pharmacokinetics, where data exist
6. Module 6 — regulatory status, stated factually
7. Closing — what the studies did not test

Module 1: What PDGF Is and How It Has Been Studied

PDGF is not a short synthetic peptide. The term describes a family of disulfide-linked, dimeric glycoproteins built from four gene products — PDGF-A, PDGF-B, PDGF-C and PDGF-D — which assemble into the dimers PDGF-AA, -AB, -BB, -CC and -DD. The name comes from the original isolation of mitogenic activity from blood platelets. Because these are full-length secreted proteins rather than 5–40 residue chains, searches for a "PDGF peptide" usually land on recombinant protein reagents, on receptor-binding fragments used in binding assays, or on the prodomain regions that regulate the longer isoforms.

Two of the four chains, PDGF-C and PDGF-D, carry an N-terminal CUB prodomain and circulate in a latent form until proteolytic processing releases the growth-factor domain. A 2022 structural and biochemical study in the Journal of Molecular Biology reported that the PDGF-D prodomain inhibited the biological activities of both PDGF-D and PDGF-B, but did so differentially between the two ligands, which the researchers used to argue that the prodomain functions as an active regulatory module rather than an inert propeptide (PMID 35777468).

How has the family been studied? Overwhelmingly in cultured cells and in mechanistic biochemistry. The papers surveyed in this course used airway smooth muscle cells, vascular smooth muscle cells, cardiomyocytes under hypoxia, carcinoma and fibroblast co-cultures, endothelial and angiogenesis models, and haematopoietic systems. A 2018 review in Molecular Aspects of Medicine framed the whole PDGF/PDGFR axis as a drug target and surveyed the pathway's biology across disease settings (PMID 29137923). A 2025 review in Seminars in Thrombosis and Hemostasis covered a narrower question, the regulatory effect of PDGF/PDGFR signalling on haematopoiesis (PMID 39608410).

Limits of the evidence in Module 1. The verified literature used here defines PDGF biochemically and biologically, but none of it establishes a human use case, a formulation, or a route of administration. Descriptions of isoforms and prodomains come from laboratory systems; nothing in this module should be read as describing what happens in an intact person.

Module 2: Mechanism as Described in the Literature

The canonical model is receptor-tyrosine-kinase signalling. PDGF dimers bind and dimerise PDGFRα and PDGFRβ, receptor autophosphorylation follows, and phosphotyrosine docking sites recruit downstream effectors that drive proliferation, migration and survival programmes. The 2018 review described this pathway and its dysregulation as the rationale for pharmacological targeting of PDGFRs (PMID 29137923).

Downstream nodes examined experimentally

Two proliferation control circuits recur in the cited work. A 2017 PLoS One study reported that enhancing the Rb/E2F and TSC/mTOR pathways together produced synergistic inhibition of PDGF-induced proliferation in vascular smooth muscle cells, which the researchers interpreted as evidence that PDGF-driven cell-cycle entry depends on both a restriction-point arm and a growth-signalling arm (PMID 28076433). A 2023 study in Cell Biology International reported that PDGF-C promoted cell proliferation partially through downregulation of BOP1, identifying a ribosome-biogenesis-associated node downstream of a less-studied ligand (PMID 37615370).

Co-receptors and trafficking

Receptor binding is not the only determinant of output. A 2017 paper in the Journal of Cell Science reported that neuropilin-1 bound PDGF-D and acted as a co-receptor in PDGF-D–PDGFRβ signalling, adding a non-kinase partner to the ligand–receptor picture (PMID 28254885). Signal duration also depends on internalisation: a 2013 study in Traffic reported that dynamin inhibitors impaired both endocytosis and the mitogenic signalling of PDGF, indicating that receptor uptake contributes to, rather than merely terminates, the proliferative response (PMID 23425318).

Endogenous versus added ligand

Not every experiment applied exogenous protein. A 2015 report in Neuropeptides examined the role of endogenous PDGF-BB in cultured cardiomyocytes exposed to hypoxia, using the cells' own ligand production as the variable of interest (PMID 25684702).

Limits of the evidence in Module 2. Every mechanism above was mapped in cultured cells or in reviews of cultured-cell work. Pathway diagrams do not predict organism-level outcomes, and inhibitor-based experiments (dynamin blockers, pathway activators) demonstrate dependency in a dish, not therapeutic behaviour.

Module 3: Reported Outcomes by Study

The table below lists the model, the endpoint and the reported direction of the result for each primary study in this course. None of these are outcome promises; they are what each paper stated it found.

A pattern is visible across these reports: much of the primary work asked how to restrain PDGF signalling rather than how to supply it. The airway and vascular studies both used PDGF as the stimulus and tested inhibitors against it (PMID 26884970, PMID 28076433), and the oncology-facing papers treated the pathway as something to block (PMID 30836770).

Limits of the evidence in Module 3. These are in vitro and review findings. No cited study measured a clinical endpoint such as symptom scores, wound closure in patients, survival or function, and no cited study administered PDGF to human volunteers. Direction of effect in a dish does not transfer to a person.

Module 4: PDGF Side Effects: What Studies Report

There are no adverse-event tables in the verified literature for this course, because none of the cited papers was a human trial. What the literature does report is a set of biological liabilities — outcomes that would be unwanted if they occurred in a living organism.

Tumour-associated signalling

The most frequently reported concern is proliferation in malignant contexts. A 2024 study in Cancer Cell International reported that PDGF-BB accelerated tongue squamous cell carcinoma through fibroblast lactate that limited miR-26a-5p and boosted mitophagy (PMID 38169376). A 2019 review in Cancer Investigation discussed PDGF-D signalling in colorectal cancer and its evaluation as a therapeutic target, that is, as something to inhibit (PMID 30836770). A 2023 study reported that PDGF-C promoted cell proliferation partially by downregulating BOP1 (PMID 37615370).

Smooth-muscle proliferation and migration

Excess smooth-muscle growth underlies airway remodelling and vascular narrowing. Researchers reported that PDGF induced proliferation and migration of airway smooth muscle cells, an effect that baicalin inhibited in that model (PMID 26884970), and a separate group reported that PDGF induced proliferation in vascular smooth muscle cells that was synergistically suppressed when Rb/E2F and TSC/mTOR signalling were enhanced (PMID 28076433).

Angiogenesis that bypasses VEGF control

A 2010 report in Oncotarget reported VEGF-independent angiogenic pathways induced by PDGF-C, which the researchers framed as a potential route of escape from VEGF-directed strategies (PMID 20871734).

Haematopoietic effects

A 2025 review described a regulatory effect of PDGF/PDGFR signalling on haematopoiesis, indicating that the axis is not confined to connective-tissue and vascular compartments (PMID 39608410).

Limits of the evidence in Module 4. None of the above is a documented human adverse event with an incidence rate. There are no reported frequencies, no dose–toxicity relationships, and no comparator arms in the cited work. Readers should treat this module as a description of biological risk signals in laboratory systems, not as a safety profile.

Module 5: Pharmacokinetics, Where Data Exist

No cited paper in this course reported a half-life, a bioavailability figure, a Cmax, an AUC, a clearance value or a human dose. That absence is itself the finding, and it is stated here rather than filled in.

What the literature does supply are determinants of how long and how strongly a PDGF signal persists at the cellular level:

• Latency and activation. The 2022 biochemistry study reported that the PDGF-D prodomain inhibited the biological activities of PDGF-D and PDGF-B differentially, meaning that availability of active ligand depends on prodomain removal rather than on ligand abundance alone (PMID 35777468).
• Receptor internalisation. Researchers reported that dynamin inhibitors impaired endocytosis and mitogenic signalling of PDGF, tying signal output to trafficking machinery (PMID 23425318).
• Co-receptor availability. A 2017 study reported that neuropilin-1 bound PDGF-D and served as a co-receptor in PDGF-D–PDGFRβ signalling, so cell-surface partner expression shapes responsiveness (PMID 28254885).
• Local production. A 2015 study examined endogenous PDGF-BB produced by cultured cardiomyocytes under hypoxia rather than ligand added from outside (PMID 25684702).

Limits of the evidence in Module 5. Cellular trafficking and activation data are not pharmacokinetics. Nothing here describes absorption, distribution, metabolism or excretion in an animal or a person, and no exposure–response relationship can be inferred from these papers.

Module 6: Regulatory Status, Stated Factually

This section is general regulatory information, not legal advice.

Approved products

Recombinant human PDGF-BB has been formulated as a prescription topical gel product approved in the United States for a specific wound indication; that product is regulated as a prescription drug with an FDA-approved label, and that label carries a boxed warning relating to malignancy. Separately, several small-molecule tyrosine kinase inhibitors that act on PDGF receptors, among other kinases, are approved oncology medicines — the pathway's status as a pharmacological target was the subject of the 2018 review in Molecular Aspects of Medicine (PMID 29137923).

Research-use-only material

The recombinant PDGF-AA, -AB, -BB, -CC and -DD proteins used in the studies above are supplied as research-use-only (RUO) reagents. RUO labelling means the material is intended for laboratory investigation, has not been evaluated by a regulator for safety or efficacy in humans, and is not authorised for diagnostic or therapeutic use. RUO status is a labelling and distribution category, not a quality endorsement.

Compounding

In the United States, compounding pharmacies operating under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act may compound from bulk drug substances only within defined statutory and list-based constraints. Recombinant growth factors such as PDGF isoforms are protein products regulated as biologics, and biological products fall outside the ordinary compounding pathways available for small-molecule active pharmaceutical ingredients. Rules differ by jurisdiction and change over time.

Limits of the evidence in Module 6. Regulatory categories describe legal status only. Approval of one PDGF-BB product for one indication says nothing about other isoforms, other routes or other uses, and none of the cited studies evaluated a marketed product.

Closing: What the Studies Did Not Test

Read as a set, the verified literature is a mechanistic body of work. The following were not examined in any paper cited on this page:

• Any administration of PDGF to human participants, at any dose, by any route.
• Any dose–response, duration or schedule in a living organism.
• Systemic pharmacokinetics: absorption, half-life, distribution or clearance.
• Long-term safety, cancer incidence in exposed subjects, or immunogenicity.
• Comparison against an approved therapy, placebo control or standard of care.
• Cosmetic, athletic, recovery or anti-ageing endpoints of any kind.
• Interaction with other compounds, medicines or supplements.

Several of the most cited findings run in the opposite direction from a "growth factor is beneficial" intuition: researchers reported that PDGF-BB accelerated a squamous carcinoma model (PMID 38169376), that PDGF-C induced angiogenesis independently of VEGF (PMID 20871734), and that PDGF-D signalling was being evaluated as a target for inhibition in colorectal cancer (PMID 30836770). Any accurate summary of this literature has to hold those reports alongside the developmental and repair-associated roles the same pathway plays.

References

• PDGF-BB accelerates TSCC via fibroblast lactates limiting miR-26a-5p and boosting mitophagy (Cancer Cell International, 2024)
• Baicalin inhibits PDGF-induced proliferation and migration of airway smooth muscle cells (International Journal of Clinical and Experimental Medicine, 2015)
• PDGF-D Prodomain Differentially Inhibits the Biological Activities of PDGF-D and PDGF-B (Journal of Molecular Biology, 2022)
• Enhanced Rb/E2F and TSC/mTOR Pathways Induce Synergistic Inhibition in PDGF-Induced Proliferation in Vascular Smooth Muscle Cells (PLoS One, 2017)
• PDGF-C promotes cell proliferation partially via downregulating BOP1 (Cell Biology International, 2023)
• The PDGF/PDGFR pathway as a drug target (Molecular Aspects of Medicine, 2018)
• Role of endogenous PDGF-BB in cultured cardiomyocytes exposed to hypoxia (Neuropeptides, 2015)
• Neuropilin 1 binds PDGF-D and is a co-receptor in PDGF-D-PDGFRβ signaling (Journal of Cell Science, 2017)
• VEGF-independent angiogenic pathways induced by PDGF-C (Oncotarget, 2010)
• Possible Role and Therapeutic Target of PDGF-D Signalling in Colorectal Cancer (Cancer Investigation, 2019)
• Regulatory Effect of PDGF/PDGFR on Hematopoiesis (Seminars in Thrombosis and Hemostasis, 2025)
• Dynamin inhibitors impair endocytosis and mitogenic signaling of PDGF (Traffic, 2013)